 WESTLAKE VILLAGE, Calif., Jan. 13, 2021 GLOBE NEWSWIRE -- Arcutis Biotherapeutics, Inc. Nasdaq: ARQT, a medical dermatology company developing innovative treatments for patients with immune-mediated dermatological diseases and conditions, today announced that it has commenced pivotal Phase 3 clinical trials evaluating topical roflumilast cream ARQ-151 as a potential treatment for atopic dermatitis AD. Roflumilast cream is a once daily topical formulation of roflumilast, a highly potent and selective phosphodiesterase type 4 inhibitor PDE4, which the Company is developing for plaque psoriasis and AD. 